Skip to main content
. 2014 Oct 13;9(10):e109756. doi: 10.1371/journal.pone.0109756

Figure 3. Time-dependent expression of the death and the decoy receptors at the surface of HCT116 p53+/+ and p53 null cells treated by bortezomib and TRAIL (or DR5-B).

Figure 3

In all experiments, cells were treated with 1 nM bortezomib and 1 ng/ml TRAIL variants alone or in combination. (A) Profiles of the death receptors at the cell surface. (B) Profiles of the decoy receptors at the cell surface. (C) Relative level of death and decoy receptors membrane expression in cells during combined treatment with TRAIL variants and bortezomib. Values in all experiments are mean ± SD of at least three independent experiments.